Nintedanib**

Vargatef banner

Nintedanib** is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.1

About nintedanib

Nintedanib is a triple angiokinase inhibitor blocking the kinase activity of vascular endothelial growth factor receptors (VEGFRs) 1–3, platelet-derived growth factor receptors (PDGFRs) α and β, and fibroblast growth factor receptors (FGFRs) 1–3. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks intracellular signalling, which is crucial for the proliferation and survival of endothelial cells as well as perivascular cells (pericytes and vascular smooth muscle cells).1

Nintedanib, when added to docetaxel, demonstrated over one year (12.6 months) median overall survival for patients with advanced lung cancer with adenocarcinoma after first-line chemotherapy (vs 10.3 months for patients receiving docetaxel alone). A further increased relative survival benefit was observed in patients with an aggressive course of disease: a median OS improvement of 3.0 months was seen in a pre-specified group of patients who progressed within 9 months after starting first-line therapy (10.9 vs 7.9 months). A median OS improvement of 3.5 months was observed following retrospective analysis of the subgroup refractory to 1st line therapy (PD as best response; 9.8 vs 6.3 months).2

The approval of nintedanib in the EU is primarily based on the positive results of the LUME-Lung 1 study of with over 1300 patients from 27 countries.2

For further information on nintedanib please see:
References: 
  1. VARGATEF Summary of Product Characteristics available at: http://ec.europa.eu/health/documents/community-register/2014/20141121130020/anx_130020_en.pdf Accessed: March 2016.
  2. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-155.
X